111 related articles for article (PubMed ID: 9106988)
1. The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.
Bates PI; Sharma HL; Murrer BA; Bernard CF; McAuliffe CA
Appl Radiat Isot; 1997 Apr; 48(4):469-76. PubMed ID: 9106988
[TBL] [Abstract][Full Text] [Related]
2. Microscale syntheses of anti-tumour platinum compounds labelled with 191Pt.
Baer J; Harrison R; McAuliffe CA; Zaki A; Sharma HL; Smith AG
Int J Appl Radiat Isot; 1985 Mar; 36(3):181-4. PubMed ID: 3888854
[TBL] [Abstract][Full Text] [Related]
3. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.
Bates PI; Sharma HL; Murrer BA; McAuliffe CA
Cancer Chemother Pharmacol; 1996; 39(1-2):170-5. PubMed ID: 8995517
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
6. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
8. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.
Xing B; Zhu H; Wang Y; Tang W
Biometals; 2000 Sep; 13(3):203-8. PubMed ID: 11127891
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
10. In vitro binding of an orally active platinum antitumor drug, JM216 to metallothionein.
Xing B; Zhu H; Shi Y; Tang W
Biometals; 2001 Mar; 14(1):51-7. PubMed ID: 11368275
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
12. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
13. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
Ando Y; Shimizu T; Nakamura K; Mushiroda T; Nakagawa T; Kodama T; Kamataki T
Br J Cancer; 1998 Nov; 78(9):1170-4. PubMed ID: 9820175
[TBL] [Abstract][Full Text] [Related]
14. Use of 191Pt radiotracer for the development of enrichment procedures to detect natural levels of platinum in biological and environmental materials.
Parent M; Cornelis R; Alt F; Strijckmans K; Dams R
Biol Trace Elem Res; 1994; 43-45():109-15. PubMed ID: 7710817
[TBL] [Abstract][Full Text] [Related]
15. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes.
Lee YA; Lee SS; Kim KM; Lee CO; Sohn YS
J Med Chem; 2000 Apr; 43(7):1409-12. PubMed ID: 10753477
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
18. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
Poon GK; Raynaud FI; Mistry P; Odell DE; Kelland LR; Harrap KR; Barnard CF; Murrer BA
J Chromatogr A; 1995 Sep; 712(1):61-6. PubMed ID: 8556156
[TBL] [Abstract][Full Text] [Related]
19. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
Amorino GP; Freeman ML; Carbone DP; Lebwohl DE; Choy H
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):399-405. PubMed ID: 10760436
[TBL] [Abstract][Full Text] [Related]
20. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
